Francesca E. Cunningham, PharmD

Opioid use incidence and prevalence rates decreased with implementation of an opioid safety initiative, whereas nonsteroidal anti-inflammatory drug rates remained constant. Rates of adverse events were higher among opioid users.

After the FDA warning and removal of rosiglitazone from the VA National Formulary, glucose control may have declined among those discontinuing rosiglitazone without receiving replacement medication.

A higher proportion of veterans who use VA pharmacy services are black, have no alternative insurance, have lower incomes, are disabled, and report poorer health.